Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Emapunil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSPO known ✓ | P30536 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | USP1 | O94782 | 2/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Emapunil SCHEMBL29388876 | 1.00 | TSPO (1.00) | TSPOALDH1A1TP53USP1RXFP1 | |
| Emapunil SCHEMBL7215605 | 0.99 | TSPO (0.98) | TSPOALDH1A1TP53USP1RXFP1 | |
| SCHEMBL7210798 | 0.94 | TSPO (0.88) | TSPOALDH1A1TP53USP1RXFP1 | |
| SCHEMBL6483612 | 0.92 | TSPO (0.85) | TSPOALDH1A1TP53RXFP1 | |
| SCHEMBL6479920 | 0.90 | TSPO (0.82) | TSPOALDH1A1 | |
| SCHEMBL7215464 | 0.88 | TSPO (0.79) | TSPOALDH1A1USP1 | |
| SCHEMBL7210455 | 0.87 | TSPO (0.77) | TSPOUSP1 | |
| SCHEMBL7210778 | 0.82 | TSPO (0.69) | TSPOALDH1A1USP1 | |
| SCHEMBL27887760 | 0.82 | TSPO (0.69) | TSPOALDH1A1USP1 | |
| SCHEMBL7215395 | 0.80 | TSPO (0.67) | TSPOALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6962921-B2 | Dementia remedies containing 2-aryl-8-oxodihydropurine derivatives as the active ingredient | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2005-11-08 | — | — | US | claimed |
| CN-1146566-C | 2-aryl-8-oxodihydropurine derivatives, process for producting same, medicinal conty. same, and intermediates thereof | �ձ���ҩ��ʽ���� | 2004-04-21 | — | — | CN | claimed |
| CN-1466587-A | Dementia therapeutic agent containing 2-aryl-8-oxodihydropurine derivative as active ingredient | �ձ���ҩ��ʽ���� | 2004-01-07 | — | — | CN | claimed |
| US-20030166667-A1 | Dementia remedies containing 2-aryl-8-oxodihydropurine derivatives as the active ingredient | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2003-09-04 | — | — | US | claimed |
| EP-1036794-B1 | 2-ARYL-8-OXODIHYDROPURINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, MEDICINAL COMPOSITIONS CONTAINING THE SAME, AND INTERMEDIATES THEREOF | DAINIPPON PHARMACEUTICAL CO (JP) | 2003-08-27 | — | — | EP | claimed |
| EP-1306378-A1 | DEMENTIA REMEDIES CONTAINING 2-ARYL-8-OXODIHYDROPURINE DERIVATIVES AS THE ACTIVE INGREDIENT | Dainippon Pharmaceutical Co., Ltd. (JP) | 2003-05-02 | — | — | EP | claimed |
| US-6372740-B1 | NERVOUS SYSTEM DISORDERS, ANTIEPILEPTIC AGENTS AND ANTIDEPRESSANTS | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2002-04-16 | — | — | US | claimed |
| CN-1284076-A | 2-aryl-8-oxodihydropurine derivatives, process for producting same, medicinal conty. same, and intermediates thereof | DAINIPPON PHARMACEUTICAL CO (JP) | 2001-02-14 | — | — | CN | claimed |
| EP-1036794-A1 | 2-ARYL-8-OXODIHYDROPURINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, MEDICINAL COMPOSITIONS CONTAINING THE SAME, AND INTERMEDIATES THEREOF | Dainippon Pharmaceutical Co., Ltd. (JP) | 2000-09-20 | — | — | EP | claimed |
| US-20240009200-A1 | TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2024-01-11 | — | — | US | disclosed |
| US-20240009200-A1 | TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2024-01-11 | — | — | US | disclosed |
| US-20240009200-A1 | TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2024-01-11 | — | — | US | disclosed |
| EP-4240353-A1 | TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | Imperial College Innovations Limited (GB) | 2023-09-13 | — | — | EP | disclosed |
| WO-2022096901-A1 | TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2022-05-12 | — | — | WO | disclosed |
| US-20030166667-A1 | Dementia remedies containing 2-aryl-8-oxodihydropurine derivatives as the active ingredient | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2003-09-04 | — | — | US | disclosed |
| EP-1036794-B1 | 2-ARYL-8-OXODIHYDROPURINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, MEDICINAL COMPOSITIONS CONTAINING THE SAME, AND INTERMEDIATES THEREOF | DAINIPPON PHARMACEUTICAL CO (JP) | 2003-08-27 | — | — | EP | disclosed |
| EP-1306378-A1 | DEMENTIA REMEDIES CONTAINING 2-ARYL-8-OXODIHYDROPURINE DERIVATIVES AS THE ACTIVE INGREDIENT | Dainippon Pharmaceutical Co., Ltd. (JP) | 2003-05-02 | — | — | EP | disclosed |
| US-6372740-B1 | NERVOUS SYSTEM DISORDERS, ANTIEPILEPTIC AGENTS AND ANTIDEPRESSANTS | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2002-04-16 | — | — | US | disclosed |
| CN-1284076-A | 2-aryl-8-oxodihydropurine derivatives, process for producting same, medicinal conty. same, and intermediates thereof | DAINIPPON PHARMACEUTICAL CO (JP) | 2001-02-14 | — | — | CN | disclosed |
| EP-1036794-A1 | 2-ARYL-8-OXODIHYDROPURINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, MEDICINAL COMPOSITIONS CONTAINING THE SAME, AND INTERMEDIATES THEREOF | Dainippon Pharmaceutical Co., Ltd. (JP) | 2000-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166667-A1 | Dementia remedies containing 2-aryl-8-oxodihydropurine derivatives as the active ingredient | TDP1, CHRM1, TPMT | TSPO 1016/4885ALDH1A1 877/4885TP53 2585/4885 |
| US-20240009200-A1 | TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | TSPO, SLC8B1, EDNRB | TSPO 1/4885ALDH1A1 2201/4885TP53 4471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.